维罗非尼

Vemurafenib (PLX4032)

	产品编号	CFN60058
	CAS编号	918504-65-1
	分子式 = 分子量	C₂₃H₁₈ClF₂N₃O₃S = 489.92
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Alkaloids
	植物来源
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
维罗非尼	CFN60058	918504-65-1	1mg	QQ客服：3004468088
维罗非尼	CFN60058	918504-65-1	5mg	QQ客服：3004468088
维罗非尼	CFN60058	918504-65-1	10mg	QQ客服：3004468088
维罗非尼	CFN60058	918504-65-1	20mg	QQ客服：3004468088

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

ChemFaces的产品在许多优秀和顶级科学期刊中被引用

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089

University of Eastern Finland (Finland)

Universidade Federal de Pernambuco (UFPE) (Brazil)

University of Queensland (Australia)

Institute of Pathophysiology Medical University of Vienna (Austria)

Sanford Burnham Medical Research Institute (USA)

FORTH-IMBB (Greece)

University of Hull (United Kingdom)

Molecular Biology Institute of Barcelona (IBMB)-CSIC (Spain)

Calcutta University (India)

Auburn University (USA)

University of Wisconsin-Madison (USA)

Lodz University of Technology (Poland)

National Hellenic Research Foundation (Greece)

Wageningen University (Netherlands)

More...

Description:

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-RafV600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Targets:

B-RafV600E | Autophagy

In vitro:

Nature,2012 Jan 26;483(7387):100-3.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.[Pubmed: 22281684]

Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug.
METHODS AND RESULTS:
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032.
CONCLUSIONS:
Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
3-乙酰氧基-27-羟基-20(29)-流明-28-羧酸甲酯; 3-Acetoxy-27-hydroxy-20(29)-lupen-28-oic acid methyl ester	CFN98306	263844-80-0	C₃₃H₅₂O₅ = 528.8	5mg	QQ客服：3004468520
Kankanoside O; Kankanoside O	CFN95737	1326304-00-0	C₁₆H₂₆O₈ = 346.4	5mg	QQ客服：3004468520
Z-DEVD-FMK; Z-DEVD-FMK	CFN60132	210344-95-9	C₃₀H₄₁FN₄O₁₂ = 668.66	5mg	QQ客服：3004468091
乙酰基表鬼臼毒素; Acetylepipodophyllotoxin	CFN99279	1180-35-4	C₂₄H₂₄O₉ = 456.5	5mg	QQ客服：3004468091

信息支持

公司简介
订购流程
付款方式
退换货政策

ChemFaces提供的产品仅用于科学研究使用，不用于诊断或治疗程序。

联系方式

电机：18607101326
传真：027-84254680
在线QQ: 3004468088
E-Mail：manager@chemfaces.com

湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房

ChemFaces为科学家，科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产。

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.0411 mL	10.2057 mL	20.4115 mL	40.823 mL	51.0287 mL
5 mM	0.4082 mL	2.0411 mL	4.0823 mL	8.1646 mL	10.2057 mL
10 mM	0.2041 mL	1.0206 mL	2.0411 mL	4.0823 mL	5.1029 mL
50 mM	0.0408 mL	0.2041 mL	0.4082 mL	0.8165 mL	1.0206 mL
100 mM	0.0204 mL	0.1021 mL	0.2041 mL	0.4082 mL	0.5103 mL